抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3171人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852818, encodeId=2f901852818ef, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=220916, objectId=e3f82209162c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f82209162c, replyNumber=0, likeNumber=120, createdTime=2022-10-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f82209162c, moduleTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3f82209162c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852790, encodeId=66ad1852e9028, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, objectType=article, longId=219199, objectId=9d6e219199ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6e219199ce, replyNumber=0, likeNumber=73, createdTime=2022-06-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6e219199ce, moduleTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6e219199ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852928, encodeId=31b0185292850, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：免疫检查点抑制剂（ICI）治疗后出现内分泌不良反应可能疗效更好, objectType=article, longId=301737, objectId=fed4301e37d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fed4301e37d0, replyNumber=0, likeNumber=76, createdTime=2023-02-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fed4301e37d0, moduleTitle=Front Oncol：免疫检查点抑制剂（ICI）治疗后出现内分泌不良反应可能疗效更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fed4301e37d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852911, encodeId=870a185291185, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, objectType=article, longId=301028, objectId=7a613010288a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a613010288a, replyNumber=0, likeNumber=81, createdTime=2022-09-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a613010288a, moduleTitle=EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a613010288a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852810, encodeId=d4d318528102c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=97, createdTime=2022-09-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852967, encodeId=4303185296e5c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=口服XPO1抑制剂「塞利尼索片」在中国大陆多地开出首批处方，极大满足骨髓瘤患者治疗需求, objectType=article, longId=727001, objectId=4760e27001e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4760e27001e5, replyNumber=0, likeNumber=75, createdTime=2022-11-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4760e27001e5, moduleTitle=口服XPO1抑制剂「塞利尼索片」在中国大陆多地开出首批处方，极大满足骨髓瘤患者治疗需求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4760e27001e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852739, encodeId=e47b1852e39d4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAHA：钠-葡萄糖协同转运蛋白抑制剂与房颤, objectType=article, longId=216436, objectId=88d621643623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88d621643623, replyNumber=0, likeNumber=72, createdTime=2022-07-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88d621643623, moduleTitle=JAHA：钠-葡萄糖协同转运蛋白抑制剂与房颤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88d621643623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852807, encodeId=09e9185280ee8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, objectType=article, longId=220296, objectId=ddf8220296a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddf8220296a1, replyNumber=0, likeNumber=56, createdTime=2022-02-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddf8220296a1, moduleTitle=Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddf8220296a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852813, encodeId=e0a3185281378, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果, objectType=article, longId=220644, objectId=1bac22064495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bac22064495, replyNumber=0, likeNumber=140, createdTime=2021-12-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bac22064495, moduleTitle=Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bac22064495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852782, encodeId=2f481852e82d2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响, objectType=article, longId=218712, objectId=149f218e125c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=149f218e125c, replyNumber=0, likeNumber=69, createdTime=2022-07-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=149f218e125c, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=149f218e125c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852900, encodeId=04c3185290020, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Diabetes Care:钠-葡萄糖共转运蛋白2抑制剂、二肽基肽酶4抑制剂和磺酰脲类药物对糖尿病酮症酸中毒风险的安全性比较, objectType=article, longId=299394, objectId=4c1a29939490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c1a29939490, replyNumber=0, likeNumber=76, createdTime=2022-09-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c1a29939490, moduleTitle=Diabetes Care:钠-葡萄糖共转运蛋白2抑制剂、二肽基肽酶4抑制剂和磺酰脲类药物对糖尿病酮症酸中毒风险的安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c1a29939490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852907, encodeId=c3c1185290e28, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAAD：JAK抑制剂治疗特应性皮炎的临床试验中老年人的代表性不足, objectType=article, longId=300570, objectId=546b3005e0ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=546b3005e0ef, replyNumber=0, likeNumber=91, createdTime=2022-07-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=546b3005e0ef, moduleTitle=JAAD：JAK抑制剂治疗特应性皮炎的临床试验中老年人的代表性不足, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=546b3005e0ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852941, encodeId=4237185294178, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=0, createdTime=2022-12-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852695, encodeId=d8271852695a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Nat Commun：淀粉样蛋白抑制剂可以恢复p53突变体的肿瘤抑制功能 , objectType=article, longId=213730, objectId=ab39213e3061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab39213e3061, replyNumber=0, likeNumber=64, createdTime=2022-05-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab39213e3061, moduleTitle=Nat Commun：淀粉样蛋白抑制剂可以恢复p53突变体的肿瘤抑制功能 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab39213e3061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852836, encodeId=f147185283642, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, objectType=article, longId=291839, objectId=14f2291839cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f2291839cd, replyNumber=0, likeNumber=67, createdTime=2022-10-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f2291839cd, moduleTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f2291839cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852770, encodeId=2f0b1852e70ae, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, objectType=article, longId=218302, objectId=3ada21830258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ada21830258, replyNumber=0, likeNumber=81, createdTime=2022-07-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ada21830258, moduleTitle=Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ada21830258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852943, encodeId=fa6618529432b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险, objectType=article, longId=723949, objectId=4428e2394910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4428e2394910, replyNumber=0, likeNumber=76, createdTime=2022-12-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4428e2394910, moduleTitle=Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4428e2394910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852985, encodeId=4d98185298559, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=EBioMedicine ：CBP/β-连环蛋白抑制剂PRI-724在丙型和乙型肝炎病毒诱导的肝硬化患者中的安全性、耐受性和抗纤维化效果, objectType=article, longId=727868, objectId=a22fe2786820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a22fe2786820, replyNumber=0, likeNumber=85, createdTime=2022-06-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a22fe2786820, moduleTitle=EBioMedicine ：CBP/β-连环蛋白抑制剂PRI-724在丙型和乙型肝炎病毒诱导的肝硬化患者中的安全性、耐受性和抗纤维化效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a22fe2786820)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852772, encodeId=6fba1852e72a5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Dig Dis Sci: 免疫抑制剂的使用会增加艰难梭菌感染复发的风险, objectType=article, longId=218356, objectId=e256218356f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e256218356f0, replyNumber=0, likeNumber=82, createdTime=2022-09-23, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e256218356f0, moduleTitle=Dig Dis Sci: 免疫抑制剂的使用会增加艰难梭菌感染复发的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e256218356f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852712, encodeId=782e1852e12fc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析, objectType=article, longId=214509, objectId=d98d214509a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d98d214509a2, replyNumber=0, likeNumber=83, createdTime=2021-10-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d98d214509a2, moduleTitle=Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d98d214509a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌

2022-10-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后

2022-06-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：免疫检查点抑制剂（ICI）治疗后出现内分泌不良反应可能疗效更好

2023-02-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

EHJ：有理有据——指导性选择强效P2Y12抑制剂治疗急性冠状动脉综合征更有效且安全！

2022-09-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2022-09-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

口服XPO1抑制剂「塞利尼索片」在中国大陆多地开出首批处方，极大满足骨髓瘤患者治疗需求

2022-11-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAHA：钠-葡萄糖协同转运蛋白抑制剂与房颤

2022-07-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：包括抗血管抑制剂，PD-1抑制剂以及肝动脉灌注化疗（HAIC）的三联疗法治疗初始不可切除肝细胞癌时手术转化能力的回顾性评估

2022-02-17

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：多受体酪氨酸激酶抑制剂卡博替尼单药治疗晚期软组织肉瘤的效果

2021-12-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Diabetes Obes Metab：SGLT-2抑制剂对T2DM患者血清尿酸水平的影响

2022-07-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Diabetes Care:钠-葡萄糖共转运蛋白2抑制剂、二肽基肽酶4抑制剂和磺酰脲类药物对糖尿病酮症酸中毒风险的安全性比较

2022-09-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAAD：JAK抑制剂治疗特应性皮炎的临床试验中老年人的代表性不足

2022-07-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-12-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Nat Commun：淀粉样蛋白抑制剂可以恢复p53突变体的肿瘤抑制功能

2022-05-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索

2022-10-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Pharmacol Ther ：2型糖尿病患者中GLP-1 RA和DPP-4抑制剂的使用与肠梗阻风险增加相关

2022-07-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Circulation：SGLT2抑制剂可降低2型糖尿病患者的高钾血症风险

2022-12-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

EBioMedicine ：CBP/β-连环蛋白抑制剂PRI-724在丙型和乙型肝炎病毒诱导的肝硬化患者中的安全性、耐受性和抗纤维化效果

2022-06-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Dig Dis Sci: 免疫抑制剂的使用会增加艰难梭菌感染复发的风险

2022-09-23

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Heart：阿司匹林与P2Y12抑制剂联合抗凝治疗对房颤的疗效分析

2021-10-19

科室
- - 订阅+
  - 更多科室
工具
服务